Immunotherapy for Breast Cancer: Updates from the San Antonio Breast Cancer Symposium 2021
Immunotherapy is now part of standard of care for some types of triple negative breast cancer, with much more research ongoing.
Tag: Triple-Negative Breast Cancer
New Treatments for Triple Negative Breast Cancer
This year we’ve seen some encouraging news with approvals of a targeted therapy and an immunotherapy for triple negative breast cancer.
5 Cancer Research Stories Worth Following – Spring 2017
Cancer research stories worth following this spring include a study on the benefits of one type of immune system therapy for patients with metastatic triple negative breast cancer.
5 Cancer Research Stories Worth Following – Winter 2017
Cancer research stories worth following this winter include a possible new use for an existing drug to prevent metastasis in triple negative breast cancer.
5 Cancer Research Stories Worth Following – Spring 2016
Cancer research stories worth following this spring include a potential new combination treatment for HER2-positive breast cancer and evidence that a gene assay may help breast cancer patients avoid unnecessary chemotherapy treatment.
5 Cancer Research Stories Worth Following – Winter 2016
Cancer research stories worth following this winter include an experimental targeted therapy for metastatic triple negative breast cancer and a study on how the financial toxicity of cancer treatment affects physical health and survival.
San Antonio Breast Cancer Symposium 2015: “These Data Belong to Our Patients”
Research findings presented at the 2015 San Antonio Breast Cancer Symposium may preview an era in which breast cancer treatments will be tailored to each patient.
6 Cancer Research Stories Worth Following – Winter 2015
What’s exciting in cancer research right now? In this post, I’ll review several of the recent stories that seem to have the great potential impact, at least from my perspective, and that I know I’ll want to follow as they develop further.
The I-SPY 2 Breast Cancer Trial: How Clinical Trials May Be Changing
In “adaptive” clinical trial design, the goal is to identify as rapidly as possible new drug therapies that show a likelihood of being successful in specific patient populations.
San Antonio Breast Cancer Symposium 2013: What Did We Learn?
My top five takeaways from the 2013 San Antonio Breast Cancer Symposium.
After 20 Years 